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Clear cell renal cell carcinoma (ccRCC) accounts for 70–80% of kidney cancer diagnoses and displays high mo-
lecular and histologic heterogeneity. Hence, it is necessary to reveal the underlying molecular mechanisms
involved in progression of ccRCC to better stratify the patients and design effective treatment strategies. Here, we
analyzed the survival outcome of ccRCC patients as a consequence of the differential expression of four transcript
isoforms of the pyruvate kinase muscle type (PKM). We first extracted a classification biomarker consisting of
eight gene pairs whose within-sample relative expression orderings (REOs) could be used to robustly classify the
patients into two groups with distinct molecular characteristics and survival outcomes. Next, we validated our
findings in a validation cohort and an independent Japanese ccRCC cohort. We finally performed drug reposi-
tioning analysis based on transcriptomic expression profiles of drug-perturbed cancer cell lines and proposed that
paracetamol, nizatidine, dimethadione and conessine can be repurposed to treat the patients in one of the subtype
of ccRCC whereas chenodeoxycholic acid, fenoterol and hexylcaine can be repurposed to treat the patients in the
other subtype.1. Introduction
Clear cell renal cell carcinoma (ccRCC) is the most common subtype
among renal cancer (Motzer et al., 2017) and ccRCC shows high inter
individual heterogeneity (Ricketts et al., 2018). Thus, it is difficult to
predict survival outcomes of patients in clinical practice and design
effective therapeutic strategies. Previous studies have already proposed
strategies for stratification of ccRCC patients into subgroups based on
different genetic and/or transcriptomic characteristics and prognoses of
the patients (Brannon et al., 2010; Cancer Genome Atlas Research, 2013;
Kosari et al., 2005; Takahashi et al., 2001). However, these studies failedZhang), adilm@scilifelab.se (A. M
orm 7 February 2020; Accepted
vier Ltd. This is an open access arto identify a clinically practical biomarker for classification of the pa-
tients at the personalized level or recommend targeted chemotherapy
regimens for these patients.
Pyruvate kinase muscle type (PKM) is an enzyme that is involved in
the final step of glycolysis and catalyzes the formation of ATP from ADP
as phosphoenolpyruvate undergoes dephosphorylation to pyruvate. It is
one of the key regulators of Warburg effect in tumors. Many studies have
reported that different alternative splicing isoforms of PKM promote
tumorigenesis (Christofk et al., 2008a; Clower et al., 2010; Yang et al.,
2012), cell proliferation (Christofk et al., 2008b; Huang et al., 2017; Li
et al., 2014; Lunt et al., 2015; Morita et al., 2018; Yang et al., 2011),ardinoglu).
14 February 2020
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
X. Li et al. Heliyon 6 (2020) e03440metastasis (Xie et al., 2019; Yang et al., 2014) and poor prognoses of
patients (Ahmed et al., 2007; Uhlen et al., 2017) in different cancers. In a
previous study, PKM isoform switch mediated by PTBP1 was found in
ccRCC (Jiang et al., 2017). Interestingly, we also found four different
isoforms of PKM play a very important role in controlling metabolism of
ccRCC (Li et al., 2019b). We have observed that the expression level of
four protein-coding transcripts of PKM, including ENST00000335181,
which is encoding PKM2 and the most studied isoform of PKM, as well as
ENST00000561609, ENST00000389093 and ENST00000568883 are
highly associated with patients’ prognoses (Li et al., 2019b). Among
them, high expression of ENST00000335181 and ENST00000561609
indicated a favorable survival while high expression of
ENST00000389093 and ENST00000568883 indicated an unfavorable
survival. Moreover, a number of conserved biological functions associ-
ated with the progression of ccRCC were oppositely dysregulated by
these transcripts. Here, we hypothesized that different molecular sub-
types among ccRCC patients can be characterized by the different
expression patterns induced by these four prognostic transcripts and
biomarkers that may be used in clinical practice can be identified.
Systems biology based approaches have been used in stratification of
patients with different metabolic diseases and certain type of cancers for
characterization of the patient subtypes (Altay et al., 2019; Benfeitas
et al., 2019; Bidkhori et al., 2018; Bjornson et al., 2015; Mardinoglu et al.,
2018). Previous studies have also proposed transcriptomics-based bio-
markers for classification of tumors based on the quantitative measure-
ment of one or multiple signature genes (Fujita et al., 2012; Jones et al.,
2005; Klatte et al., 2009; Kosari et al., 2005; Zhao et al., 2006). However,
this kind of transcriptional signatures are rarely used in clinical practice
due to technological and translational barriers (Winslow et al., 2012).
Besides problems in tissue sampling and quality control, an important
factor is experimental batch effect which brings high variation of gene
expression induced by the different laboratory conditions and personnel
(Guan et al., 2018). To solve these problems, the use of biomarkers based
on the within-sample relative expression orderings (REOs) of gene pairs
has been proposed (Guo et al., 2018; Qi et al., 2016a, 2016b).
REOs-based biomarkers are robust against batch effects, invariant to
monotone data normalization (Eddy et al., 2010; Wang et al., 2013) and
poor sample preparation (Chen et al., 2017b; Cheng et al., 2017; Liu
et al., 2017).
In this study, we used the genes dysregulated by the prognostic
transcripts of PKM to extract classification biomarker instead of using
themselves. Since different transcripts of PKM share similar sequence, it
may be difficult to design distinct primers to detect their relative abun-
dance when using real-time PCR. Thus, gene pair biomarker is more
feasible and practical in clinical diagnosis. We applied REOs-based
method to identify biomarkers for classification of ccRCC by extracting
the expression profiles of genes which were consistently negatively
dysregulated by the four favorable and unfavorable prognostic tran-
scripts of PKM. We developed a REOs-based biomarker using the global
gene expression profiling of ccRCC in The Cancer Genome Atlas (TCGA)
database and stratified the patients into two subtypes exhibiting different
transcriptomic expression patterns and different patient prognosis. We
also validated our findings in TCGA database as well as in another in-
dependent Japanese cohort. We finally proposed several candidate drugs
that can be used in treatment of each subtype based on transcriptomic
expression profiles of drug-perturbed cancer cell lines from Connectivity
Map 2.0 (CMap2).
2. Result
2.1. Identification of signature gene set associated with four prognostic
transcripts of PKM
In a recent study, we have found that there are molecular subtypes
that could be characterized by the expression of the four different
prognostic PKM transcripts (Li et al., 2019b). In order to develop a2REOs-based biomarker, we identified a signature gene set associated with
these four transcripts based on the gene expression profiles of TCGA
ccRCC samples. We performed differential expression analysis between
the tumor samples from patients with high (top 25%) and low (bottom
25%) expression of each favorable transcript, and identified 2,010
consistently significantly (FDR <1.0e-5) differentially expressed genes
(DEGs) for the two favorable transcripts (Figure 1). Similarly, we iden-
tified 5,469 DEGs consistently significantly (FDR <1.0e-5) DEGs for the
two unfavorable transcripts. We found that the two sets of DEGs has a
significant overlap (n ¼ 1,135; hypergeometric distribution test, p <
1.11e-16). We also observed that the concordance score of these over-
lapped genes is 100%, which means the up-regulated genes associated
with high expression of favorable transcripts within these 1,135 genes
are all down-regulated when the unfavorable transcripts exhibit high
expression; and vice versa.
We followed-up survival information from the corresponding patients
and found that 539 of the 1,135 genes (of which 305 and 234 are
favorable and unfavorable, respectively) are significantly (univariate Cox
model, FDR <0.01) associated with patients’ overall survival (OS). To
identify the associated biological functions with these 539 genes, we
performed GO term enrichment analysis and observed that these genes
are significantly enriched in RNA splicing, RNA catabolic process and
nuclear transport pathways (FDR<0.05; Table S1). Therefore, we
concluded that these 539 genes may be used as the core signature genes
that are associated with the differential alternative splicing of PKM
among ccRCC patients and may be used for classification of tumor
samples.
We calculated the co-expression coefficients between the expression
of the 539 signature genes and found two major clusters in which all
favorable genes are positively co-expressed while all unfavorable genes
are negatively co-expressed in the opposite cluster using the hierarchical
clustering (Figure 2A). Based on the expression profiles of these 539
signature genes, we employed consensus clustering to classify TCGA
ccRCC samples into distinct stable sub-groups through repeated sub-
sampling and clustering (Wilkerson and Hayes, 2010). As shown in
Figure 2B, we determined an optimum number of two clusters, cluster 1
and 2, based on the lowest proportion of ambiguous clustering (Senba-
baoglu et al., 2014). Using survival analysis, we observed the patients
whose tumor samples classified in cluster 1 (N ¼ 231) had significantly
shorter OS than those classified in cluster 2 (N ¼ 297) with statistical
significance (log-rank test, P ¼ 6.73e-07; Figure 2C). The results
demonstrated that there are two different molecular subtypes in ccRCC
with significantly different survival outcomes which are strongly asso-
ciated with the function of the two favorable and two unfavorable
transcripts.
2.2. Development of the REOs-based classification biomarker
To identify a biomarker that can be used in the clinical practice, we
next focused on development of a REOs-based classification biomarker
based on the gene expression profiles of the 539 signature genes. In brief,
REOs-based biomarkers employs gene pairs with consistently reversed
expression orders between the two molecular groups as indicators, and
screens for a minimum combination of these gene pairs that serves as risk
indicators for classification. In order to obtain a robust biomarker, we
generated 100 training and 100 validation datasets by randomly select-
ing from TCGA ccRCC cohort and randomly separated the samples into
two respective groups with 70% and 30% samples. We identified 171
gene pairs that exhibited consistent reverse gene pairs in all training
datasets. We next generated 17,100 reverse gene pair combinations with
a forward selection procedure and selected a final REOs-based biomarker
consisted of eight reverse gene pairs with an optimal mean F-score of
0.9725 in all training datasets (Figure 2D). The full screening process are
shown in Figure 1 and detailed in Method section.
Within this eight gene pairs, if more than four gene pairs exhibited
reversal REOs in a sample, this sample would be classified into the high-
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Figure 1. The flowchart for developing and validating the ccRCC classification biomarker. In brief, we extract the 1135 overlapped DEGs associated with favorable
and unfavorable transcripts, and select 539 prognostic signature genes from them. Next, we screen gene pair biomarker using randomly generated training dataset.
Lastly, we validate the performance of the biomarker in all randomly generated validation dataset and an independent Japanese ccRCC dataset.
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group (Figure 2D). We tested these gene pairs in the 100 validation
datasets, and found that these gene pairs also showed a good classifica-
tion accuracy with amean F-score 0.9742.We also tested these gene pairs
using the complete TCGA cohort, and this biomarker classified 231
samples into high-risk group and 297 samples into low-risk group.
Notably, these two groups showed significantly different OS (Figure 2E;
log rank test, P ¼ 1.69e-07).
2.3. Validation of the REOs-based classification biomarker
To validate if these gene pairs can be used as a biomarker for classi-
fication of ccRCC samples, we tested these gene pairs in 100 ccRCC3samples obtained from an independent Japanese cohort. The biomarker
classified 35 samples as high-risk group and 65 samples as low-risk
group, and these two groups showed significantly different OS
(Figure 2F, P ¼ 7.46e-05). We next investigated whether the high and
low-risk groups identified in both TCGA and Japanese cohorts exhibited
similar biological differences. We extracted the top 20% most significant
DEGs (n ¼ 2,694) between high and low-risk groups in both the TCGA
and Japanese cohorts, and observed a significant overlap between them
(n ¼ 1,463; hypergeometric distribution test, p < 1.11e-16) with a
concordance score 100%. In addition, we identified 66 and 80 GO terms
that are significantly enriched with upregulated genes (FDR<1.0e-05) in
the high-risk group of the TCGA and Japanese cohorts, respectively, and
found that 55 of them are common in both cohorts (Figure 3).
Figure 2. Molecular classification and
prognostic prediction of patients by classifi-
cation biomarker. (A) Hierarchical clustering
of 539 signature genes based on the corre-
lation between genes. The spearman corre-
lation coefficients between genes were used
for clustering. (B) Consensus clustering for
TCGA ccRCC patients based on the expres-
sion values of the 539 signature genes. (C)
Kaplan-Meier plot of OS of two clusters
identified by consensus clustering in TCGA
ccRCC cohort. (D) The composition of clas-
sification biomarker and voting rule. (E)
Kaplan-Meier plot of OS of high- and low-risk
identified by classification biomarker in
TCGA ccRCC cohort. (F) Kaplan-Meier plot of
OS of high- and low-risk identified by clas-
sification biomarker in Japanese ccRCC
cohort.
X. Li et al. Heliyon 6 (2020) e03440Specifically, the high-risk group was characterized by upregulated genes
involved in ATP synthesis, mitochondrial respiratory process, oxidative
phosphorylation, ribonucleotide and purine nucleotide metabolic pro-
cess, RNA catabolic process, protein targeting to ER and membrane
pathways. And the low-risk group was characterized by upregulated
genes involved in histone modification and covalent chromatin modifi-
cation pathways. The results suggested the molecular subtypes identified
by our analysis also have consistent biological differences. Moreover,
these 55 GO terms included all 27 GO terms that we recently reported to
be associated with the four different prognostic transcripts in pan cancer
analysis (Li et al., 2019b). We also identified three GO terms that are
significantly enriched with downregulated genes in the high-risk group4for both cohorts, and two of them, which are the histone modification
and covalent chromatin modification pathways, are common in both
groups. These results further indicated that the molecular subtypes
stratified by the gene pairs are functionally related to the four prognostic
transcripts of PKM.
Further, we compared our REOs-based classification with previously
reported TCGA (m1 to m4) and ccA/ccB classification schemes (Brannon
et al., 2010; Cancer Genome Atlas Research, 2013) (Figure 4). In TCGA
cohort, approximately 96% of TCGA m1 tumors were involved in our
low-risk group, and m1 group was also reported with the best prognoses
in TCGA classification scheme. In addition, 73% of TCGA tumors in both
m2 and m4 subtypes were involved in our high-risk groups, and they
Figure 3. The dysregulated biological functions in high- and low-risk ccRCC groups and. Heat map of the p values (on the negative log 10 scale) for the enriched GO
terms in TCGA and Japanese KIRC cohort. Red color denotes the GO terms enriched with up-regulated genes. Blue color denotes the GO terms enriched with down-
regulated genes. * FDR<1.0e-05.
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Figure 4. Pie charts showing the intersection of the different classification schemes for ccRCC. ‘m1’, ‘m2’, ‘m3’ and ‘m4’ indicate the molecular subtypes proposed by
TCGA, and ‘ccA’ and ‘ccB’ are molecular subtypes reported by another previous study.
X. Li et al. Heliyon 6 (2020) e03440were also shown to be with the poorest prognoses in TCGA classification.
These results demonstrated that the high and low-risk groups classified
by our biomarker are reinforced by the previously observed survival
outcomes m1, m2 and m4. Notably, the high and low-risk groups5respectively accounted for 42% and 58% of tumors previously reported
as unclassified (m3) in the TCGA classification scheme. In Japanese
cohort, 71% of ccA and 80% of ccB were observed in the low and
high-risk groups, respectively. We found that the favorable survival for
X. Li et al. Heliyon 6 (2020) e03440ccA cases again reinforced the low-risk group classification based on our
gene pairs used as a biomarker (Figure 4).
2.4. Drug repositioning for treatment of ccRCC subtypes
In addition to classification of the tumors, we also performed drug
repositioning analysis to identify drug candidates that can be used in
treatment of each subtype (Figure 5). We assumed that if a drug could
reverse the dysregulated gene expression pattern from a tumor subtype to
normal pattern, it could be potentially useful for treating the specific
tumor subtype. We used a method developed in our previous study for
drug repurposing (Turanli et al., 2018, 2019a, 2019b) and found several
drugs that could be used for treatment of the high and low-risk groups
(see Method). We found that four different drugs including paracetamol,Figure 5. The flowchart f
6nizatidine, dimethadione and conessine may be used to reverse the gene
expression in samples from high-risk group, since over 80%
drug-perturbed genes were mapped to the DEGs between these samples
and normal samples. Paracetamol is an analgesic and antipyretic drug
with the effect of anti-inflammatory and inhibits the production of
multiple oxidants (Graham et al., 2013). Interestingly, it has been re-
ported that paracetamol inhibits the cell proliferation and induces cell
apoptosis in pancreatic cancer (Malsy et al., 2017), ovarian cancer and
lung cancer cells (Lian et al., 2018). Nizatidine is an antagonist of his-
tamine H2 receptors and these receptors are associated with cell prolif-
eration, embryonic development and tumor growth
(Fernandez-Nogueira et al., 2018). It has been shown that nizatidine was
recommended to be added into the combination therapy for cancer
treatment (Barton-Burke, 1996; Ben-Sasson, 2007; Feitelberg et al.,or drug repositioning.
X. Li et al. Heliyon 6 (2020) e034402013). Conessine, a steroid alkaloid, decreases basal NF-κB activity,
regulates autophagy, has anti-inflammatory effect (Kim et al., 2016,
2018) and is proposed as a potential anti-cancer drug. Therefore, the
anti-cancer effects of three of the proposed drugs have been reported in
previous studies.
Similarly, we found that three different drugs including chenodeox-
ycholic acid, fenoterol and hexylcaine, may be used to reverse the gene
expression in samples of low-risk group towards normal samples. It has
been reported that natural as well as synthetic bile acids can modulate
cell cycle and induce apoptosis in cancer cells (Horowitz et al., 2007; Kim
et al., 2006). Chenodeoxycholic acid, a bile acid, shows anti-proliferative
activity in human cancer cells (Faustino et al., 2016). Beta-adrenergic
signaling pathway has been found to promote the initiation and pro-
gression of cancer including inflammation, angiogenesis, apoptosis, cell
motility, DNA damage repair and epithelial-mesenchymal transition
(Cole and Sood, 2012). Fenoterol, a beta-adrenoreceptor agonist, has
been shown to inhibit the proliferation of glioblastomas and astrocy-
tomas cells (Bernier et al., 2013; Toll et al., 2011). Hexylcaine, a
short-acting local anesthetic, has also been used to treat cancer (Gleich,
2000) even its anti-cancer activity is still unclear. In this context, these
three drugs may also be potentially used for treatment of the subtype of
ccRCC patients.
Moreover, we identified the gene targets for each of the drugs using
DrugBank database (Wishart et al., 2006). HRH2, encoding the histamine
H2 receptor, has been reported as the gene target of nizatidine (Meredith
et al., 1985). We observed that it is significantly up-regulated in the
samples of high-risk group compared to normal samples. It has been
demonstrated that in vitro and in vivo histamine-induced tumor cell
proliferation can be blocked by H2 antagonists (Deva and Jameson, 2012;
Natori et al., 2005; Tomita et al., 2003). Thus, nizatidine may be used as a
promising drug for the patients classified in the high-risk group. On the
other hand, GPBAR1, encoding an enzyme of the G protein-coupled re-
ceptor superfamily, has been reported as a target of chenodeoxycholic
acid. It has been shown that GPBAR1 antagonizes kidney cancer cell
proliferation and migration (Su et al., 2017). Based on our analysis, we
have observed that GPBAR1 is significantly downregulated in the
low-risk group compared to normal samples. Thus, chenodeoxycholic
acid, as an activator of GPBAR1, may be used as a promising drug for
treating the patients classified in the low-risk group.
3. Discussion
PKM is one of the important regulators of Warburg effect in different
human cancers (Dayton et al., 2016). Our recent study showed that four
different transcripts of PKM mediate opposite survival outcomes for
ccRCC patients. In this study, we identified the core signature genes
which were consistently dysregulated by these four prognostic tran-
scripts of PKM. Using these signature genes, we identified eight gene
pairs whose within-samples REOs could be used to classify patients into
two groups with significantly different OS. Although RNA sequencing
data was used for the biomarker classification in this study, much
cheaper technics could be used once the biomarker is used in clinical
practice. For instance, we could use real-time PCR, which is much
cheaper compared to the sequencing approach, to determine the relative
abundance of the genes involved in these 8 gene pairs to classify a ccRCC
tumor sample since we only need to detect their REOs.
Real-time PCR has been used for commercial mRNA-based gene sig-
natures. One FDA-approved signature is AlloMap®, consisting of 20
genes, for estimating the risk of acute cellular rejection in heart trans-
plant recipients (Starling et al., 2006). Another FDA-approved signature
is Oncotype DX®, consisting 21 genes, for estimating the risk of distant
recurrence in tamoxifen-treated patients with node-negative, estro-
gen-receptor-positive breast cancer (Paik et al., 2004). Both of the sig-
natures used in classification of patients into different risk groups by
comparing their risk scores summarized from expression levels of the
signature genes with preset risk score thresholds. However, the preset7thresholds from the training dataset cannot be directly applied to inde-
pendent dataset since the gene expression levels are sensitive to batch
effects and platform differences (Qi et al., 2016a). To solve this problem,
the tissue samples must be sent to the specified laboratories for mea-
surement with uniform quality control and data normalization, which
brings great limitations for wide application of these signatures. In
contrast, the relative abundance of two genes in a gene pair is much
easier to be estimated by real-time PCR with appropriate performance
since REOs-based biomarkers are relatively insensitive to both experi-
mental and bioinformatics variations, which could greatly facilitate the
use of REOs-based biomarker in clinical practice.
The genes involved in our classification of ccRCC tumor samples also
showed closed relationship with tumor development. For instance, RP9,
one of genes in the REOs gene pairs, plays an important role in pre-mRNA
splicing and could interact with well-known oncogene PIM-1 (Maita
et al., 2000). MYO9A, encodes an unconventional myosin, which is
required for collective migration of epithelial cells and thus serves as a
potent promoter in progression and metastasis of cancers of epithelial
origin (Friedl and Gilmour, 2009; Ouderkirk and Krendel, 2014). TAZ
encodes tafazzin whose overexpression promotes tumorigenicity in many
cancers and its inhibition also induces tumor cell apoptosis (Chen et al.,
2017a; Li et al., 2019a; Pathak et al., 2014). GADD45GIP1, also known as
CRIF1, encodes a nuclear-localized protein that may be induced by TP53
and regulates cell cycle. CRIF1 is a novel transcriptional coactivator of
STAT3 which is a well-known oncogene in multiple human cancers
(Kwon et al., 2008). However, CRIF1 was recruited to the upstream
promoter region of TP53 to suppress cell cycle progression in HCT116
cells (Yan et al., 2017). Thus, the role of CRIF1 is controversial in cancer.
SNRNP200 encodes a component of U5 snRNP-specific proteins of spli-
ceosome. It has been shown that overexpression of SNRNP200 was
associated with tumor aggressiveness in prostate cancer (Jimenez-Vacas
et al., 2020). PIK3CB is involved in the PI3K signaling pathway which is
frequently dysregulated in cancer. Inhibition of PIK3CB remarkably
suppressed cell growth, migration and enhanced apoptosis in glioblas-
toma (Cen et al., 2018; Pridham et al., 2018). NOLC1 functions as a
chaperone for shuttling between the nucleolus and cytoplasm (Meier and
Blobel, 1992). It has been reported that enhancement ofNOLC1 promotes
cell senescence and represses hepatocellular carcinoma cell proliferation
by disturbing the organization of nucleolus (Yuan et al., 2017).
The immunotherapy is widely used in ccRCC since the disturbance of
different immunological pathways were observed in ccRCC (Lopez-Bel-
tran et al., 2018). In this study, we found some of our biomarker genes are
potential targets for immunotherapy. TAZ also acts as a regulator in
immune evasion of cancer by positively modulating the expression of
PD-L1 in mRNA and protein level (Janse van Rensburg et al., 2018),
which is a potential maker for immunotherapy. In our analysis, both TAZ
and PD-L1 are significantly highly expressed in high- or low-risk samples
compared with normal samples. Especially, the expression of TAZ is
much higher in high-risk patients than low-risk patients, suggesting that
targeting TAZ is a more promising treatment strategy for high-risk pa-
tients besides PD-L1 immunotherapy. MYO9A is highly expressed in
immune cells and plays an important role in regulation of macrophage
shape and motility (Bahler et al., 2011). In our analysis, MYO9A was
significantly down-regulated in high-risk samples compared with
low-risk and normal samples, suggesting the innate immune response
may be weak in high-risk ccRCC patients. IBTK encodes the inhibitor of
Bruton tyrosine kinase which is required for B cell survival, differentia-
tion and activation (Fiume et al., 2009). In our analysis, the expression of
IBTK was increasingly down-regulated in normal, low-risk and high-risk
samples, suggesting that B cell immune system is active in ccRCC. NBR1
encodes a specific autophagy receptor. It has been reported that
NBR1-deficient mice have defective T helper 2 cell differentiation (Yang
et al., 2010). The histone methyltransferase ASH1L is involved in the
regulation of regulatory T cell polarization (Xia et al., 2017). In our
analysis, both the expression of NBR1 and ASH1L were increasingly
down-regulated in normal, low-risk and high-risk samples, suggesting
X. Li et al. Heliyon 6 (2020) e03440that T cell immune system may be impaired in ccRCC. PIK3CB is critical
in neutrophil activation by immune complexes (Kulkarni et al., 2011),
which is significantly down-regulated in the high-risk samples compared
to low-risk and normal samples.
In conclusion, we identified two molecular subtypes of ccRCC pa-
tients with high and low-risk of mortality, and developed a REOs-based
classification biomarker which could be used to classify the ccRCC pa-
tients into these subtypes at personalized level. In addition, we suggested
specific treatment strategies for each subtype based on their global gene
expression patterns and drug repositioning. Therefore, it is worthwhile to
further explore the potential clinical use of the here identified biomarker
in assisting clinical diagnosis and treatment of ccRCC patients.
4. Materials and methods
4.1. Data and preprocessing
The TCGA transcript-expression level profiles (TPM and count values)
of ccRCC and matched normal kidney samples was downloaded from
https://osf.io/gqrz9 (Tatlow and Piccolo, 2016) on November 27, 2018,
which was quantified by Kallisto (Bray et al., 2016) based on the GEN-
CODE reference transcriptome (version 24). The clinical information of
TCGA samples was downloaded through R package TCGAbiolinks
(Colaprico et al., 2016). The whole-exome sequence data of 100 ccRCC
samples of patients from Japanese cohort (Sato et al., 2013) was down-
loaded from European Genome-phenome Archive (accession number:
EGAS00001000509). BEDTools (Quinlan and Hall, 2010) was used for
converting BAM to FASTQ file. Kallisto was used for estimating the count
and TPM values of transcripts based on the same reference transcriptome
of TCGA data. The sum value of the multiple transcripts of a gene was
used as the expression value of this gene. The genes with average TPM
values > 1 in ccRCC patients were analyzed.
4.2. Differential expression analysis
DESeq2 (Love et al., 2014) was used to identify DEGs between two
groups. The raw count values of genes were used as input of DESeq2. The
Benjamini-Hochberg (BH) procedure was used to estimate FDR.
4.3. Overlapping of two lists of DEGs
If DEG list 1 with L1 genes and DEG list 2 with L2 genes have k
overlapping genes and s of these genes shows the same directions which
means high expression of these genes indicates favorable/unfavorable
survival or group 1/2 in both lists, the probability of observing at least s
consistent genes by chance can be calculated according to the following
cumulative hypergeometric distribution model:
P¼ 1
Xs1
i¼0

L2
i

L L2
L1 i


L
L1
 (1)
where L represents the number of the background genes commonly
detected in the datasets fromwhich the DEGs are extracted. The two DEG
lists were considered to be significantly overlapping if P < 0.05.
The concordance score s/k is used to evaluate the consistency of DEGs
between the two lists. Obviously, the score ranges from 0 to 1, and the
higher concordance score suggests the better consistency of two lists of
DEGs.
4.4. Consensus clustering
Consensus clustering (Wilkerson and Hayes, 2010) was used for
tumor classification based on the normalized expression profiles of
signature genes by Z-score transformation. To achieve robust clusters, the8data was resampled for 1000 times by considering 80% samples and
signature genes resampling. The resampled data was transformed into a
similarity matrix, termed as consensus matrix. K-means clustering was
used to stratify samples based on the consensus matrix. The number of
optimum cluster was determined by the lowest proportion of ambiguous
clustering.
4.5. Survival analysis
The univariate Cox regression model was used to evaluate the cor-
relation of gene expression levels with OS. Survival curves were esti-
mated by the Kaplan-Meier method and compared with the log-rank test.
4.6. Functional enrichment analysis
GO enrichment was performed by the enrichGo function in R package
ClusterProfiler (Yu et al., 2012), in which the hypergeometric distribu-
tion was used to calculate the statistical significance of biological path-
ways enriched with DEGs of interest.
4.7. Development of the REOs-based biomarker
In each sample, the REO of every two signature genes (i and j) is
denoted as either Gi>Gj or Gi<Gj exclusively, where Gi and Gj represent
the expression values of gene i and j, respectively. For a given gene pair
(Gi and Gj), we used Fisher's exact test to evaluate whether the frequency
of group 1 samples with a specific REO pattern (Gi > Gj or Gi < Gj) was
significantly different from that in group 2 samples in each training
dataset. The P values are adjusted using BH procedure. The gene pairs
detected with 0.05 FDR control and over 70% difference of the frequency
of their REOs between two groups were denoted as reversed gene pairs.
The overlapped reversed gene pairs consistently identified from all the
training datasets were selected as the candidate signature gene pairs.
Totally, we found 171 signature gene pairs. For each signature gene pair,
according to their within-sample REO, we classified the samples of each
training dataset into high or low-risk groups and then evaluated the
sensitivity and specificity of this gene pair. Here, the sensitivity is defined
as the ratio of correctly identified high risk samples to all high-risk
samples and the specificity is defined as the ratio of correctly identified
low-risk samples to all low-risk samples. Then, from these signature gene
pairs, we performed a forward selection procedure in each training
dataset to search a set of gene pairs that achieved the highest F-score
value, a harmonic mean of sensitivity and specificity, which is calculated
as follows:
F score¼ 2ðsensitivity  specificityÞðsensitivityþ specificityÞ (2)
Taking each of the 171 gene pairs as a seed, we added another gene
pair to the biomarker at a time until the F-score did not increase. The
classification rule is that a sample is classified into high or low-risk group
if the majority of the REOs of the set of gene pairs within this sample vote
for high or low-risk. We got 171 biomarkers based on each training
dataset. Totally, we got 17,100 candidate biomarkers for all the 100
training datasets. Finally, we selected the biomarker with the lowest (1-
F1)2þ(1-F2)2þ∙∙∙þ(1-Fn)2 as the final biomarker, in which Fn is the F-
score value in the nth training dataset.
4.8. Application of CMap2 data to drug discovery
The pre-procession of CMap2 data was described in our previous
study (Turanli et al., 2019b). In brief, the gene expression profiles of
three cell lines, HL60, MCF2 and PC3, were downloaded from https:
//portals. broadinstitute.org/cmap/(CMap Build 02). As shown in
Figure 5, a single treatment cell line and control were selected to
calculate Log2FC of genes by comparison between the two cases for each
X. Li et al. Heliyon 6 (2020) e03440cell line. We normalized the log2FC matrix with 12,228 genes and 683
drugs to z-score matrix and further transformed it to P value matrix.
Then, the confidence score was calculated per each drug-gene interaction
using the P values from three cell lines. An approximation confidence
score to 1 was assumed as the higher confidence level. The drug-gene
pairs with CS > 0.5 were used in further analysis. If over 80%
drug-perturbed genes with CS > 0.5 were mapped to the DEGs between
one subtype of cancer samples and normal samples, this drug is consid-
ered to have reverse effect on the dysregulated gene expression in this
subtype of cancer samples.
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